New diabetes combo aims to beat standard care in Head-to-Head trial
NCT ID NCT06246799
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares two initial drug combinations for people recently diagnosed with type 2 diabetes. One group gets pioglitazone plus tirzepatide (Mounjaro), the other gets metformin plus sitagliptin. The study will track how well each combo lowers blood sugar and how long the effect lasts in 256 adults over several years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pioglitazone and tirzepatide (Mounjaro) combination
What this could lead to
If successful, this could show that starting with a pioglitazone and tirzepatide combo helps more people with new diabetes reach and maintain healthy blood sugar levels than the standard metformin and sitagliptin combo.
What could go wrong
This is a mid-stage trial with 256 people, so results may not apply to everyone. Both drug combos have side effects, and the study will not prove a cure—diabetes will still need ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (ADULT ONSET) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Health Science Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
University Health System Texas Diabetic Institute
RECRUITINGSan Antonio, Texas, 78207, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••